;PMID: 11571630
;source_file_2858.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..151] = [t:43..151]
;2)section:[e:155..258] = [t:155..258]
;3)section:[e:262..335] = [t:262..335]
;4)sentence:[e:339..412] = [t:339..412]
;5)sentence:[e:413..600] = [t:413..600]
;6)sentence:[e:601..745] = [t:601..745]
;7)sentence:[e:746..865] = [t:746..865]
;8)sentence:[e:866..971] = [t:866..971]
;9)sentence:[e:973..1092] = [t:973..1092]
;10)sentence:[e:1093..1179] = [t:1093..1179]
;11)sentence:[e:1180..1316] = [t:1180..1316]
;12)section:[e:1320..1365] = [t:1320..1365]

;section 0 Span:0..37
;Neoplasia.  2001 Jul-Aug;3(4):304-13.
(SEC
  (FRAG (NNP:[0..9] Neoplasia) (.:[9..10] .) (CD:[12..16] 2001)
        (CC:[17..21] Jul-) (IN:[21..25] Aug;) (CC:[25..27] 3-LRB-)
        (CD:[27..28] 4) (-RRB-:[28..29] -RRB-) (::[29..30] :)
        (CD:[30..36] 304-13) (.:[36..37] .)))

;sentence 1 Span:43..151
;Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant
;growth  in neuroblastoma cell lines.
;[43..48]:gene-generic:"Bcl-2"
;[53..58]:gene-generic:"M-Myc"
;[82..88]:gene-protein:"IGF-IR"
;[105..114]:malignancy-clinical-stage:"malignant"
;[126..139]:malignancy-type:"neuroblastoma"
(SENT
  (S-HLN
    (NP-SBJ
      (NML (NN:[43..48] Bcl-2) (CC:[49..52] and) (NN:[53..58] M-Myc))
      (NN:[59..71] coexpression))
    (VP (VBZ:[72..81] increases)
      (NP
        (NP (NN:[82..88] IGF-IR))
        (CC:[89..92] and)
        (NP
          (NP (NNS:[93..101] features))
          (PP (IN:[102..104] of)
            (NP (JJ:[105..114] malignant) (NN:[115..121] growth)))))
      (PP-LOC (IN:[123..125] in)
        (NP (NN:[126..139] neuroblastoma) (NN:[140..144] cell)
            (NNS:[145..150] lines))))
    (.:[150..151] .)))

;section 2 Span:155..258
;Jasty R, van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P, Opipari
;A,  Feldman E, Castle VP.
(SEC
  (FRAG (NNP:[155..160] Jasty) (NNP:[161..162] R) (,:[162..163] ,)
        (NNP:[164..167] van) (NNP:[168..173] Golen) (NNP:[174..175] C)
        (,:[175..176] ,) (NNP:[177..180] Lin) (NNP:[181..183] HJ)
        (,:[183..184] ,) (NNP:[185..192] Solomon) (NNP:[193..194] G)
        (,:[194..195] ,) (NNP:[196..208] Heidelberger) (NNP:[209..211] K,)
        (NNP:[212..221] Polverini) (NNP:[222..224] P,) (NNP:[225..232] Opipari)
        (NNP:[233..234] A) (,:[234..235] ,) (NNP:[237..244] Feldman)
        (NNP:[245..246] E) (,:[246..247] ,) (NNP:[248..254] Castle)
        (NN:[255..257] VP) (.:[257..258] .)))

;section 3 Span:262..335
;Department of Pediatrics, Medical College of Ohio, Toledo, OH 43614, USA.
(SEC
  (FRAG (NNP:[262..272] Department) (IN:[273..275] of)
        (NNP:[276..286] Pediatrics) (,:[286..287] ,) (NNP:[288..295] Medical)
        (NNP:[296..303] College) (IN:[304..306] of) (NNP:[307..311] Ohio)
        (,:[311..312] ,) (NNP:[313..319] Toledo) (,:[319..320] ,)
        (NNP:[321..323] OH) (CD:[324..329] 43614) (,:[329..330] ,)
        (NNP:[331..334] USA) (.:[334..335] .)))

;sentence 4 Span:339..412
;The bcl-2 and c-myc oncogenes cooperate to transform multiple cell types.
;[343..348]:gene-rna:"bcl-2"
;[353..358]:gene-rna:"c-myc"
(SENT
  (S
    (NP-SBJ-2 (DT:[339..342] The)
      (NML
        (NML (NN:[343..348] bcl-2)
          (NML-1 (-NONE-:[348..348] *P*)))
        (CC:[349..352] and)
        (NML (NN:[353..358] c-myc)
          (NML-1 (NNS:[359..368] oncogenes)))))
    (VP (VBP:[369..378] cooperate)
      (S-PRP
        (NP-SBJ-2 (-NONE-:[378..378] *))
        (VP (TO:[379..381] to)
          (VP (VB:[382..391] transform)
            (NP (JJ:[392..400] multiple) (NN:[401..405] cell)
                (NNS:[406..411] types))))))
    (.:[411..412] .)))

;sentence 5 Span:413..600
;In the  pediatric malignancy NB(2), Bcl-2 is highly expressed. In tumors with
;a poor  prognosis, N-Myc, a protein homologous to c-Myc, is overexpressed as
;a result of  gene amplification.
;[421..430]:malignancy-developmental-state:"pediatric"
;[442..447]:malignancy-type:"NB(2)"
;[449..454]:gene-protein:"Bcl-2"
;[510..515]:gene-protein:"N-Myc"
;[541..546]:gene-protein:"c-Myc"
;[586..599]:variation-type:"amplification"
(SENT
  (S
    (PP (IN:[413..415] In)
      (NP
        (NP (DT:[416..419] the) (JJ:[421..430] pediatric)
            (NN:[431..441] malignancy))
        (NP (NN:[442..447] NB-LRB-2-RRB-))))
    (,:[447..448] ,)
    (NP-SBJ-1 (NN:[449..454] Bcl-2))
    (VP (VBZ:[455..457] is)
      (ADVP (RB:[458..464] highly))
      (VP (VBN:[465..474] expressed)
        (NP-1 (-NONE-:[474..474] *))))
    (.:[474..475] .))
  (S
    (PP-LOC (IN:[476..478] In)
      (NP
        (NP (NNS:[479..485] tumors))
        (PP (IN:[486..490] with)
          (NP (DT:[491..492] a) (JJ:[493..497] poor) (NN:[499..508] prognosis)))))
    (,:[508..509] ,)
    (NP-SBJ-2
      (NP (NN:[510..515] N-Myc))
      (,:[515..516] ,)
      (NP
        (NP (DT:[517..518] a) (NN:[519..526] protein))
        (ADJP (JJ:[527..537] homologous)
          (PP (TO:[538..540] to)
            (NP (NN:[541..546] c-Myc))))))
    (,:[546..547] ,)
    (VP (VBZ:[548..550] is)
      (VP (VBN:[551..564] overexpressed)
        (NP-2 (-NONE-:[564..564] *))
        (PP (IN:[565..567] as)
          (NP
            (NP (DT:[568..569] a) (NN:[570..576] result))
            (PP (IN:[577..579] of)
              (NP (NN:[581..585] gene) (NN:[586..599] amplification)))))))
    (.:[599..600] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[413..600]::S:S:

;sentence 6 Span:601..745
;The present study was designed to determine whether Bcl-2  cooperates with
;N-Myc to bestow a tumorigenic phenotype to neuroblastoma (NB)  cells.
;[653..658]:gene-protein:"Bcl-2"
;[676..681]:gene-protein:"N-Myc"
;[719..732]:malignancy-type:"neuroblastoma"
;[734..736]:malignancy-type:"NB"
(SENT
  (S
    (NP-SBJ-1 (DT:[601..604] The) (JJ:[605..612] present) (NN:[613..618] study))
    (VP (VBD:[619..622] was)
      (VP (VBN:[623..631] designed)
        (NP-1 (-NONE-:[631..631] *))
        (S-PRP
          (NP-SBJ (-NONE-:[631..631] *))
          (VP (TO:[632..634] to)
            (VP (VB:[635..644] determine)
              (SBAR (IN:[645..652] whether)
                (S
                  (NP-SBJ (NN:[653..658] Bcl-2))
                  (VP (VBZ:[660..670] cooperates)
                    (PP-CLR (IN:[671..675] with)
                      (NP (NN:[676..681] N-Myc)))
                    (S-PRP
                      (NP-SBJ (-NONE-:[681..681] *))
                      (VP (TO:[682..684] to)
                        (VP (VB:[685..691] bestow)
                          (NP (DT:[692..693] a) (JJ:[694..705] tumorigenic)
                              (NN:[706..715] phenotype))
                          (PP-CLR (TO:[716..718] to)
                            (NP
                              (NML
                                (NML (NN:[719..732] neuroblastoma))
                                (NML (-LRB-:[733..734] -LRB-) (NN:[734..736] NB)
                                     (-RRB-:[736..737] -RRB-)))
                              (NNS:[739..744] cells))))))))))))))
    (.:[744..745] .)))

;sentence 7 Span:746..865
;NB cell lines that at baseline express neither Bcl-2 nor N-Myc were  stably
;transfected to express these gene products.
;[746..748]:malignancy-type:"NB"
;[793..798]:gene-protein:"Bcl-2"
;[803..808]:gene-protein:"N-Myc"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[746..748] NB) (NN:[749..753] cell) (NNS:[754..759] lines))
      (SBAR
        (WHNP-1 (WDT:[760..764] that))
        (S
          (NP-SBJ-1 (-NONE-:[764..764] *T*))
          (PP (IN:[765..767] at)
            (NP (NN:[768..776] baseline)))
          (VP (VBP:[777..784] express)
            (NP (CC:[785..792] neither) (NN:[793..798] Bcl-2)
                (CC:[799..802] nor) (NN:[803..808] N-Myc))))))
    (VP (VBD:[809..813] were)
      (ADVP (RB:[815..821] stably))
      (VP (VBN:[822..833] transfected)
        (NP-2 (-NONE-:[833..833] *))
        (S-PRP
          (NP-SBJ-2 (-NONE-:[833..833] *))
          (VP (TO:[834..836] to)
            (VP (VB:[837..844] express)
              (NP (DT:[845..850] these) (NN:[851..855] gene)
                  (NNS:[856..864] products)))))))
    (.:[864..865] .)))

;sentence 8 Span:866..971
;In this model, we found Bcl-2  rescues N-Myc-expressing cells from apoptosis
;induced by serum withdrawal.
;[890..895]:gene-protein:"Bcl-2"
;[905..910]:gene-protein:"N-Myc"
(SENT
  (S
    (PP (IN:[866..868] In)
      (NP (DT:[869..873] this) (NN:[874..879] model)))
    (,:[879..880] ,)
    (NP-SBJ (PRP:[881..883] we))
    (VP (VBD:[884..889] found)
      (SBAR (-NONE-:[889..889] 0)
        (S
          (NP-SBJ (NN:[890..895] Bcl-2))
          (VP (VBZ:[897..904] rescues)
            (NP
              (ADJP (NN:[905..910] N-Myc) (HYPH:[910..911] -)
                    (VBG:[911..921] expressing))
              (NNS:[922..927] cells))
            (PP (IN:[928..932] from)
              (NP
                (NP (NN:[933..942] apoptosis))
                (VP (VBN:[943..950] induced)
                  (NP (-NONE-:[950..950] *))
                  (PP (IN:[951..953] by)
                    (NP-LGS (NN:[954..959] serum) (NN:[960..970] withdrawal))))))))))
    (.:[970..971] .)))

;sentence 9 Span:973..1092
;Coexpression of Bcl-2 and N-Myc supports growth in low serum conditions and 
;anchorage-independent growth in soft agar.
;[989..994]:gene-protein:"Bcl-2"
;[999..1004]:gene-protein:"N-Myc"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[973..985] Coexpression))
      (PP (IN:[986..988] of)
        (NP (NN:[989..994] Bcl-2) (CC:[995..998] and) (NN:[999..1004] N-Myc))))
    (VP (VBZ:[1005..1013] supports)
      (NP
        (NP (NN:[1014..1020] growth))
        (PP (IN:[1021..1023] in)
          (NP (JJ:[1024..1027] low) (NN:[1028..1033] serum)
              (NNS:[1034..1044] conditions))))
      (CC:[1045..1048] and)
      (NP
        (NP
          (ADJP (NN:[1050..1059] anchorage) (HYPH:[1059..1060] -)
                (JJ:[1060..1071] independent))
          (NN:[1072..1078] growth))
        (PP (IN:[1079..1081] in)
          (NP (JJ:[1082..1086] soft) (NN:[1087..1091] agar)))))
    (.:[1091..1092] .)))

;sentence 10 Span:1093..1179
;Similarly, in vivo tumorigenic and  angiogenic activity was dependent on
;coexpression.
(SENT
  (S
    (ADVP (RB:[1093..1102] Similarly))
    (,:[1102..1103] ,)
    (NP-SBJ
      (ADJP (FW:[1104..1106] in) (FW:[1107..1111] vivo))
      (ADJP (JJ:[1112..1123] tumorigenic) (CC:[1124..1127] and)
            (JJ:[1129..1139] angiogenic))
      (NN:[1140..1148] activity))
    (VP (VBD:[1149..1152] was)
      (ADJP-PRD (JJ:[1153..1162] dependent)
        (PP (IN:[1163..1165] on)
          (NP (NN:[1166..1178] coexpression)))))
    (.:[1178..1179] .)))

;sentence 11 Span:1180..1316
;Our data further suggests  that the mechanism underlying these changes
;involves the receptor for insulin  growth factor type I (IGF-IR).
;[1264..1306]:gene-protein:"receptor for insulin  growth factor type I"
;[1308..1314]:gene-protein:"IGF-IR"
(SENT
  (S
    (NP-SBJ (PRP$:[1180..1183] Our) (NNS:[1184..1188] data))
    (ADVP (RBR:[1189..1196] further))
    (VP (VBZ:[1197..1205] suggests)
      (SBAR (IN:[1207..1211] that)
        (S
          (NP-SBJ
            (NP (DT:[1212..1215] the) (NN:[1216..1225] mechanism))
            (VP (VBG:[1226..1236] underlying)
              (NP (DT:[1237..1242] these) (NNS:[1243..1250] changes))))
          (VP (VBZ:[1251..1259] involves)
            (NP (DT:[1260..1263] the)
              (NML
                (NML
                  (NML (NN:[1264..1272] receptor))
                  (PP (IN:[1273..1276] for)
                    (NP
                      (NML (NN:[1277..1284] insulin) (NN:[1286..1292] growth)
                           (NN:[1293..1299] factor))
                      (NN:[1300..1304] type) (CD:[1305..1306] I))))
                (NML (-LRB-:[1307..1308] -LRB-) (NN:[1308..1314] IGF-IR)
                     (-RRB-:[1314..1315] -RRB-))))))))
    (.:[1315..1316] .)))

;section 12 Span:1320..1365
;PMID: 11571630 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1320..1324] PMID) (::[1324..1325] :) (CD:[1326..1334] 11571630)
        (NN:[1335..1336] -LSB-) (NNP:[1336..1342] PubMed) (::[1343..1344] -)
        (NN:[1345..1352] indexed) (IN:[1353..1356] for)
        (NNP:[1357..1365] MEDLINE-RSB-)))
